Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcitriol is the hormonally active form of vitamin D3 and is classified as a vitamin D analog. It is primarily used to treat and prevent low levels of calcium (hypocalcemia) and bone disease in patients with chronic kidney disease or parathyroid disorders. Calcitriol acts by binding to the vitamin D receptor (VDR), a nuclear receptor that regulates gene transcription. This interaction increases intestinal absorption of calcium and phosphate, enhances renal tubular reabsorption of calcium, stimulates release of calcium from bone via osteoblast-mediated activation of osteoclasts (through RANKL), and suppresses parathyroid hormone (PTH) synthesis by direct genomic effects in parathyroid cells[1][5][6]. Calcitriol also has immunomodulatory and anti-proliferative properties[3]. It is indicated for secondary hyperparathyroidism in chronic kidney disease patients not on dialysis or on dialysis; hypoparathyroidism; metabolic bone diseases associated with renal failure; and other conditions involving abnormal calcium metabolism[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcitriol.